Reply to Du et al.—Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and Stroke

Thank you, Dr Du, for the commentary 1 Du L. Wang P. Chen H. Zhang Y. Ma J. Obvious differences between GLP1RAs and SGLT2is in the outcomes of heart failure, renal failure, and stroke. Can J Cardiol. 2023; 39: 90 Google Scholar regarding our article, “The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis.” 2 Ali M.U. Mancini G. Fitzpatrick-Lewis D. et al. The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta-analysis. Can J Cardiol. 2022; 38: 1201-1210 Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar The differential effectiveness of the 2 classes regarding the aforementioned critical end points was highlighted in the review’s results and discussion sections. In addition, distinctions were made on a clinical basis in the guideline (published in parallel) and specifically concerning the absence of dedicated trials for GLP-1RAs in patients with heart failure or chronic kidney disease. We do emphasise, with prominence, the issue of stroke reduction with GLP-1RAs as well. Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and StrokeCanadian Journal of CardiologyVol. 39Issue 1PreviewAli et al.1 conducted a wonderful and comprehensive meta-analysis1 based on all the available cardiovascular outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2is; 11 CVOTs) and glucagon-like peptide 1 receptor agonists (GLP1RAs; 8 CVOTs), drawing their main conclusion that both SGLT2is and GLP1RAs yielded the statistically significant benefits across most cardiorenal end points in the populations studied. This conclusion only emphasises the similarity between GLP1RAs and SGLT2is in cardiorenal benefits, but ignores the differences between them in specific cardiorenal outcomes. Full-Text PDF The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysisCanadian Journal of CardiologyVol. 38Issue 8PreviewEvidence for the cardiorenal risk reduction properties of antihyperglycemic medications originally prescribed for type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) is rapidly emerging. We completed a meta-analysis of recent literature to provide evidence-based estimates of benefit across various populations and outcomes. Full-Text PDF